Australia - English - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - escitalopram oxalate, quantity: 25.551 mg/ml (equivalent: escitalopram, qty 20 mg/ml) - oral liquid, solution - excipient ingredients: sodium hydroxide; ethanol; purified water; propyl gallate; citric acid - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - escitalopram oxalate, quantity: 25.54 mg (equivalent: escitalopram, qty 20 mg) - tablet, film coated - excipient ingredients: purified talc; microcrystalline cellulose; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; purified water; macrogol 400 - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - escitalopram oxalate, quantity: 12.77 mg (equivalent: escitalopram, qty 10 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; purified talc; titanium dioxide; hypromellose; purified water; macrogol 400 - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - brexpiprazole, quantity: 4 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; maize starch; microcrystalline cellulose; lactose monohydrate; titanium dioxide; hypromellose; purified talc - rexulti is indicated in adult patients for the treatment of schizophrenia.

Australia - English - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - brexpiprazole, quantity: 2 mg - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; microcrystalline cellulose; hyprolose; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; iron oxide black - rexulti is indicated in adult patients for the treatment of schizophrenia.

Australia - English - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - brexpiprazole, quantity: 3 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; hyprolose; maize starch; titanium dioxide; hypromellose; purified talc; iron oxide red; iron oxide black - rexulti is indicated in adult patients for the treatment of schizophrenia.

Australia - English - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - brexpiprazole, quantity: 1 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; lactose monohydrate; maize starch; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; iron oxide yellow - rexulti is indicated in adult patients for the treatment of schizophrenia.

Australia - English - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - vortioxetine hydrobromide, quantity: 6.355 mg (equivalent: vortioxetine, qty 5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; hyprolose; sodium starch glycollate type a; mannitol; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - treatment of major depressive disorder in adults including prevention of relapse. vortioxetine is not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - vortioxetine hydrobromide, quantity: 19.065 mg (equivalent: vortioxetine, qty 15 mg) - tablet, film coated - excipient ingredients: magnesium stearate; mannitol; sodium starch glycollate type a; hyprolose; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 400 - treatment of major depressive disorder in adults including prevention of relapse. vortioxetine is not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - vortioxetine hydrobromide, quantity: 25.42 mg (equivalent: vortioxetine, qty 20 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; magnesium stearate; hyprolose; microcrystalline cellulose; mannitol; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - treatment of major depressive disorder in adults including prevention of relapse. vortioxetine is not indicated for paediatric use.